Why the study?
The study was conducted to explore the link between the C-reactive protein/albumin ratio and the no-reflow phenomenon during PCI in non-STEMI patients.
Does the C-reactive protein/albumin ratio predict no-reflow in non-STEMI patients undergoing PCI?
Does the C-reactive protein/albumin ratio predict no-reflow in non-STEMI patients undergoing PCI?
The C-reactive protein/albumin ratio may serve as a novel and useful inflammatory marker to predict the no-reflow phenomenon in non-STEMI patients prior to PCI.
Answers are grounded in this paper and cite their sources.
Suggests the C-reactive protein/albumin ratio may help stratify no-.
Introduction: The focus of this research was to explore the link between CRP (C-reactive protein) /albumin ratio (CAR), a novel inflammatory response marker, and no-reflow (NR) phenomena in non-ST elevation myocardial infarction (non-STEMI) patients during percutaneous coronary intervention (PCI). Methods: The current study recruited 209 non-STEMI participants who underwent PCI. The patients were divided into two groups based on their post-intervention Thrombolysis in Myocardial Infarction (TIMI) flow grade; those with and without NR. Results: In all, 30 non-STEMI patients (6.9%) had NR after PCI. CAR values were substantially greater in the NR group. The CAR was identified to be a determinant of the NR (OR: 1.250, 95% CI: 1.033-1.513, P=0.02), although CRP and albumin were not independently related with NR in the multivariate analysis. In our investigation, low density lipoprotein-cholesterol levels and high thrombus burden were also predictors of the occurrence of NR. According to receiver operating characteristic curve evaluation, the optimal value of CAR was>1.4 with 60% sensitivity and 47% specificity in detecting NR in non-STEMI patients following PCI. Conclusion: To the best of knowledge, this is the first investigation to demonstrate that the CAR, a new and useful inflammatory marker, can be utilized as a predictor of NR in patients with non-STEMI prior to PCI.
No takes yet. Share an insight, caveat, or question.
Tosu et al. (2022) studied this question.
Synapse has enriched 5 closely related papers on similar clinical questions. Consider them for comparative context: